The day at a glance · 3 min read
Mood · Risk-Off
-42
Sentiment, −100 to +100
UNH decline
12%-12%
Managed Care Under Regulatory Pressure
Dow contribution
Nearly half
Managed Care Under Regulatory Pressure
LLY 2026 M&A total
$32B
Big Pharma M&A Activity
Key driverUnitedHealth fell sharply on proposed CMS anti-fraud rule, dragging healthcare sector lower despite positive FDA approvals and pipeline progress
Daily briefHealthcare· Money365.Market AI ·

Healthcare Selloff: UNH Down 12% on CMS Fraud Rule

Managed care under regulatory pressure while Regeneron wins approval for siRNA therapy; Lilly's M&A wave reaches $32B

Managed Care Under Regulatory Pressure

Bearish
UNH
01UNH▼ -10.21%
UnitedHealth Group ($UNH) fell 12% following a proposed CMS anti-fraud rule, with Senator Warren stating that healthcare giants take a cut at every step. The common stock decline accounted for nearly half of the Dow's drop and marked the company's third consecutive session of more than 1% declines.
02
Humana also experienced significant declines on the same regulatory development, reflecting sector-wide concerns about increased scrutiny of managed care practices.

Big Pharma M&A Activity

Bullish

Calytrix Bio deal value

Up to $1.5B

Analyst target

$1,600
01LLY
Eli Lilly ($LLY) agreed to buy closely held Calytrix Bio in a deal that could be worth up to $1.5 billion, bringing the drugmaker's total acquisition wave in 2026 to more than $32 billion. The acquisition spree focuses on building out Lilly's cancer and immunology businesses, according to Bloomberg. An analyst initiated coverage with a buy rating and $1,600 target, citing volume growth outweighing pricing pressure as the pipeline advances.
02ABBV
AbbVie ($ABBV) announced a strategic collaboration with DISCO Pharmaceuticals to advance next-generation AND-gated bispecific therapeutics for solid tumors. The collaboration leverages DISCO's proprietary DISCOtech surfaceome mapping platform together with AbbVie's global oncology research and development expertise, with AbbVie receiving the option to exclusively license selected programs after DISCO completes specified research activities.

FDA Approvals & Pipeline Progress

Neutral

Melanoma vaccine efficacy

42% risk reduction-42%

MRNA 90-day return

+47.61%+47.61%

BMY dividend yield

4.58%

Debt margin reduction

0.75 ppt-0.75 ppt
01REGN
Regeneron Pharmaceuticals ($REGN) received FDA approval for Livsayis (cemdisiran), the first and only siRNA therapy for generalized myasthenia gravis and the only treatment with four-times-a-year subcutaneous dosing. The approval was based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control maintained throughout three-month dosing intervals, marking Regeneron's first approved siRNA therapy and neurology medicine.
02BMY▼ -2.92%
Bristol Myers Squibb ($BMY) advanced its strategic protein degradation partnership with Evotec, receiving a second Investigational New Drug acceptance from the FDA for a cereblon E3 ligase modulator. The first candidate produced under the partnership entered a Phase 1 clinical trial in advanced clear cell renal cell carcinoma in March 2026, while Evotec shares climbed 2% on the announcement. Bristol-Myers offers a 4.58% dividend yield with strong profitability, though analysts noted investors should watch payout sustainability and balance-sheet risks.
03MRNA▼ -4.84%
Moderna ($MRNA) saw its common stock trade at $196.79 after a sharp one-day decline of 4.84% and seven-day decline of 20.87%, despite the 90-day return showing gains of 47.61%. The company's melanoma vaccine plus Keytruda cut the risk of recurrence or death by 42% in Phase 3 trials, yet the stock declined as investors assessed the results. Moderna reworked its debt deal, cutting interest margins on existing and delayed draw term loans by 0.75 percentage points and pushing key maturities and borrowing availability further into the next decade.

Pipeline Setbacks

Bearish
01MRK▼ -3.90%
Merck ($MRK) halted clinical development of blood cancer drug candidate nemtabrutinib after a recent internal review. The decision ends all Phase 3 BELLWAVE program studies after data indicated the benefit to risk profile did not justify continuation, closing out one of Merck's late-stage hematology assets and removing a potential future option in its oncology portfolio. The company also announced that Thomas H. Glocer will retire from the board of directors in May 2027.

MedTech Manufacturing Expansion

Neutral
01DXCM
Dexcom ($DXCM) officially opened its state-of-the-art manufacturing facility in Athenry, County Galway, marking a major milestone in the company's investment in Ireland and its manufacturing presence in Europe, the Middle East and Africa. The continuous glucose monitoring leader celebrated the commercial production milestone at the new facility.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy